CLUN21035 / S1900E / Baumgart
Basic Study Information
Purpose:
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous
non-small cell lung cancer that is stage IV or has come back (recurrent) and has a
specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may
cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation,
may help stop the growth of tumor cells.
Location: University of Rochester
Lead Researcher (Principal Investigator)
Lead Researcher:
Megan Baumgart
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search